Thomas F. Pajak
#151,209
Most Influential Person Now
Thomas F. Pajak's AcademicInfluence.com Rankings
Thomas F. Pajakmedical Degrees
Medical
#2910
World Rank
#3354
Historical Rank
Oncology
#194
World Rank
#200
Historical Rank
Download Badge
Medical
Why Is Thomas F. Pajak Influential?
(Suggest an Edit or Addition)Thomas F. Pajak's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) (1995) (4148)
- Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. (2003) (2745)
- Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. (2004) (2682)
- Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005) (1389)
- INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. (2002) (1358)
- Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. (1998) (1301)
- A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 (1999) (1019)
- Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis (2006) (1005)
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. (1996) (961)
- Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. (2013) (949)
- Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group (1987) (580)
- Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. (2003) (573)
- Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. (2012) (399)
- A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. (2000) (376)
- Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. (1989) (368)
- Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. (1982) (337)
- Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. (1995) (331)
- The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. (1993) (323)
- The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. (2001) (253)
- Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. (1993) (222)
- Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study (1987) (214)
- A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy‐radiation therapy versus cyclophosphamide‐radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation (1980) (213)
- Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. (1994) (200)
- Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. (2000) (193)
- Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group. (1989) (190)
- Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long‐term results of the radiation therapy oncology group study 81‐17 (1990) (187)
- Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. (2006) (181)
- TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. (2007) (181)
- p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (1997) (178)
- Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (2006) (174)
- Precisely defining high‐risk operable head and neck tumors based on rtog #85‐03 and #88‐24: Targets for postoperative radiochemotherapy? (1998) (173)
- Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report. (1991) (153)
- Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG). (1987) (152)
- Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. (1990) (146)
- Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. (1982) (145)
- Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. (2009) (145)
- Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. (1996) (144)
- Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. (1999) (137)
- A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. (2004) (133)
- Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. (1988) (132)
- Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. (1980) (129)
- The effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation. (1983) (118)
- Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). (2007) (113)
- College of American Pathologists Conference XXXV: Solid tumor prognostic factors - Which, how and so what? Summary document and recommendations for implementation (2000) (111)
- Technically accurate intracavitary insertions improve pelvic control and survival among patients with locally advanced carcinoma of the uterine cervix. (1994) (108)
- Analysis of the probability and risk of cause-specific failure. (1994) (104)
- Hyperfractionated or accelerated radiotherapy for head and neck cancer. (2010) (104)
- interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts new evidence for accelerated proliferation from radiation therapy oncology group protocol 8313 (1992) (100)
- Multimodality therapy of localized unresectable pancreatic adenocarcinoma (1984) (94)
- ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. (1991) (94)
- Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. (1990) (93)
- Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24. (1997) (91)
- Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups (2002) (91)
- Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. (1979) (89)
- Compliance with breast‐conservation standards for patients with early‐stage breast carcinoma (2003) (89)
- Results of re-excisional biopsy of the primary tumor in preparation for definitive irradiation of patients with early stage breast cancer. (1986) (88)
- A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. (1987) (83)
- Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. (1995) (80)
- Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. (2009) (79)
- Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. (1980) (77)
- Prognostic factors for loco/regional control and metastasis and the impact on survival. (1986) (71)
- Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. (2008) (68)
- Predicting the response of head and neck cancers to radiation therapy with a multivariate modelling system: an analysis of the RTOG head and neck registry. (1984) (67)
- Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study. (1987) (67)
- Effect of age on therapeutic response and survival in advanced Hodgkin's disease. (1982) (66)
- Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer. (1988) (65)
- The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol (1993) (65)
- Improved response and survival to combined cisplatin and radiation in non‐keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors (1987) (62)
- Radiation therapy alone or in combination with surgery in head and neck cancer (1985) (60)
- Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor (2009) (58)
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. (1994) (58)
- Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. (2006) (57)
- Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. (1987) (56)
- Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. (1996) (54)
- Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. (1999) (54)
- A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. (1993) (54)
- Excisional biopsy, axillary node dissection and definitive radiotherapy for Stages I and II breast cancer. (1985) (52)
- Emotional well‐being does not predict survival in head and neck cancer patients (2008) (51)
- Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. (1982) (49)
- Survival and prognosis of patients with astrocytoma with atypical or anaplastic features (2005) (48)
- Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. (1997) (48)
- Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience. (1982) (48)
- A new effective four‐drug combination of CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea) (NSC‐79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease (1980) (47)
- Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. (1985) (46)
- Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal (1999) (46)
- Treatment of head and neck cancer. (2008) (46)
- A comparative study of a bcnu containing 4‐drug program versus mopp versus 3‐drug combinations in advanced Hodgkin's disease. A cooperative study by the cancer and leukemia group B (1979) (41)
- A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). (1989) (40)
- Statistical issues in tumor marker studies. (2000) (39)
- College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. (2000) (38)
- Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. (1986) (37)
- Analysis of neutron radiotherapy treatment complications. (1986) (36)
- Vincristine, prednisone and L‐asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse (1978) (36)
- Lung cancer as a second primary (1978) (35)
- Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma (2005) (34)
- Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery. (1999) (33)
- Workshop report: Organ preservation strategies in advanced head and neck cancer—Current status and future directions (1999) (32)
- Evaluation of Preoperative Radiation Therapy in Operable Colorectal Cancer (1994) (32)
- A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity (2010) (32)
- Early Rehabilitative Care in Community Hospitals: Effect on Quality of Survivorship Following a Stroke (1974) (31)
- Impact of initial quality control review on study outcome in lung and head/neck cancer studies--review of the Radiation Therapy Oncology Group experience. (1989) (31)
- Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial. (1989) (31)
- Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B (1981) (30)
- Twice‐daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the radiation therapy oncology group 88—05 (1994) (30)
- Definitive radiotherapy ± erythropoietin for squamous cell carcinma of the head and neck: Preliminary report of RTOG 99–03 (2004) (28)
- The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. (1984) (28)
- Response rate and survival in myeloma patients receiving prednisone alone. (1985) (28)
- Locally recurrent breast carcinoma: the effect of adjuvant chemotherapy on prognosis. (1983) (27)
- The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol. (1993) (27)
- Randomized clinical trial of cystosine arabinoside and 6‐thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia (1977) (26)
- Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. (1982) (26)
- Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08. (1994) (25)
- Survey of brachytherapy practice in the United States: a report of the Clinical Research Committee of the American Endocurietherapy Society. (1995) (25)
- Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. (1998) (24)
- Cyclophosphamide, doxorubicin, vincristine, and low‐dose continuous infusion bleomycin in non‐Hodgkin's lymphoma: Cancer and leukemia group B study #7804 (1982) (24)
- Treatment of advanced lymphomas with bleomycin (NSC-125066). (1976) (24)
- 5-year results of cisplatin and fluorouracil infusion in head and neck cancer. (1991) (24)
- Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. (2012) (23)
- Thymic irradiation. An approach to chronic lymphocytic leukemia. (1974) (22)
- Five‐Year Survival After Hyperfractionated Radiation Therapy for Non‐Small‐Cell Carcinoma of the Lung (NSCCL): Results of RTOG Protocol 81–08 (1991) (22)
- Analysis of early and lats deaths on RTOG non-small cell lung carcinoma trials vs. CALGB 8433 (1991) (21)
- Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience (1982) (21)
- The management of malignant gliomas with radiation therapy: Therapeutic results and research strategies (1991) (21)
- Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. (1977) (21)
- 26: A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma of The Vocal Cord (2006) (20)
- Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. (1981) (19)
- Fast Neutron Radiation for Inoperable and Recurrent Salivary Gland Cancers (1989) (19)
- Randomized dose-searching phase ILE/II trials of fractionation in radiation therapy for cancer. (1991) (19)
- Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. (1994) (18)
- 136 Dose escalation without split-course chemoradiation for anal cancer: Results of a phase II RTOG study (1997) (17)
- Significant adbantage of chemo-radiotherapy compared to radiation alone in randomized phase III trial for patients with esophageal cancer: An intergroup study (1991) (17)
- Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. (1979) (17)
- The relationship of infield recurrences to prescribed tumor dose in small cell carcinoma of the lung (1981) (16)
- Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. (1997) (16)
- Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study. (1981) (14)
- Fast neutrons and misonidazole for malignant astrocytomas. (1985) (14)
- Chemotherapy following Surgery for Head and Neck Cancer: A Radiation Therapy Oncology Group Study (1989) (13)
- Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. (1993) (13)
- Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: Results of a Correlative Study From the Radiation Therapy Oncology Group (RTOG) 90-03 Trial (2007) (13)
- Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. (1977) (13)
- “Compensated” Split‐Course Versus Continuous Radiation Therapy of Carcinoma of the Tonsillar Fossa: Final Results of a Prospective Randomized Clinical Trial of the Radiation Therapy Oncology Group (1993) (13)
- In response to Bentzen et al., IJROBP 32:1531-1534; 1995. (1995) (13)
- Combined therapy for resectable head and neck cancer. A phase 3 intergroup study. (1989) (12)
- 25 : Long-Term Survival Results of a Phase III Intergroup Trial (RTOG 95-01) of Surgery Followed by Radiotherapy vs. Radiochemotherapy for Resectable High Risk Squamous Cell Carcinoma of the Head And Neck (2006) (12)
- Preliminary report on phase III RTOG studies of extended-field irradiation in carcinoma of the prostate. (1982) (12)
- The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited (2017) (11)
- A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity (2007) (11)
- LENT: a good beginning but... (1995) (11)
- Considerations in designing and analyzing surgical adjuvant study in resected stage I and II carcinoma of the lung (1979) (10)
- Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/intergroup phase III trial (2002) (10)
- Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience (1979) (10)
- Combination chemotherapy of non-Hodgkin lymphoma. (1978) (10)
- Applications of Data Bases and AI/Expert Systems in Radiation Therapy (1988) (10)
- Phase II study of ICRF-159 in non-Hodgkin's lymphomas. (1978) (10)
- Minimum Full Sequences of 2 N-M Resolution Iii Plans (1975) (10)
- Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. (1998) (10)
- Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. (1988) (10)
- Interruptions of high-dose radiation therapy for non-small cell carcinoma of the lung decrease long-term survival in favorable patients (1992) (8)
- Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. (1983) (8)
- Does residual tumor adversely impact on the outcome of patients undergoing definitive irradiation for early stage breast cancer (1986) (8)
- Evaluation of a Neutron Boost in Head and Neck Cancer Results of the Randomized RTOG Trial 78–08 (1986) (8)
- Procarbazine, vinblastine, and actinomycin D in stage III and IV melanoma with or without methanol-extracted residue of Bacillus Calmette-Guérin. (1979) (7)
- Chemotherapy as predictor of compliance (1994) (7)
- Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies. (1994) (7)
- Breast cancer in young women treated definitively with radiotherapy: An early report (1984) (6)
- Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3. (1975) (6)
- Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience. (1979) (6)
- College of American Pathologists Conference XXXV: Solid Tumor Prognostic Factors—Which, How and So What? (2009) (6)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Head and Neck Cancer Committee. (2001) (6)
- Bleomycin (NSC-125066) therapy of responsive solid tumors. (1976) (6)
- Small cell anaplastic carcinoma of the lung. The Cancer and Leukemia Group B Experience. (1982) (6)
- Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience. (1979) (5)
- Development of surgical quality‐control mechanisms in large‐scale prospective trials: Head and neck intergroup report (1991) (5)
- Fast neutron therapy for malignant astrocytomas (2004) (5)
- Effect of the methanol extraction residue of Bacillus Calmette‐Guerin in advanced Hodgkin's disease (1982) (5)
- Phase II study of chlorozotocin in non-small cell carcinoma of the lung. (1981) (5)
- The radiation therapy oncology group experience altered fractionation in lung cancer (1993) (5)
- 1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531 (1997) (5)
- Maintenance management of acute nonlymphocytic leukemia. (1981) (5)
- Head and neck cancer committee (2001) (5)
- Statistical power for a long-term survival trial with a time-dependent treatment effect. (2000) (4)
- Surgical quality control in head and neck cancer. Study 73-03 of the Radiation Therapy Oncology Group. (1989) (4)
- A Radiation Therapy Oncology Group experience: chemotherapy/radiation therapy of lung cancer (1993) (4)
- Effect of trimethylcolchicinic acid methyl ether d-tartrate (TMCA) on Hodgkin's and non-Hodgkin's lymphoma. (1976) (4)
- Phase I alternate-day dose study of chromomycin A3. (1976) (4)
- Outcome comparisons of four radiation therapy oncology group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: Encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT). (2004) (4)
- In response to Drs. Dubben, Beck-Bornholdt, and Llogie. (2002) (4)
- Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. (1979) (3)
- Radiation Therapy Oncology Group (RTOG) trials for head and neck cancer. (2000) (3)
- Chapter 14 – NITROSOUREAS IN THE THERAPY OF HODGKIN'S DISEASE (1981) (3)
- In response to Dr. Denham et al. (1996) (3)
- Translational Research Program (2001) (3)
- Hyperfractioned or accelerated radiotherapy in head and neck cancer: a meta‐analysis (2007) (3)
- In response to bentzen and thames: Regarding dose-response relationships for late radiation effects in the head and neck: Analysis of RTOG 8313 trial, fu et al. IJROBP 32:577–588; 1995 (1996) (3)
- S11 5 MA – ALTERED FRACTIONATION RADIOTHERAPY-REPORT OF RTOG STUDIES (1991) (2)
- Preliminary results of combined radiation and chemotherapy in the treatment of Hodgkin's disease (A randomized study of cancer and leukemia group B) (1979) (2)
- Interfraction interval is major determinant of late effects, but not acute effects or tumor control, with hyperfractionated irradiation (HFX) of carcinomas of upper respiratory and digestive tracts (URDT) (1990) (2)
- Socio-demographic variables influence outcome in Radiation Therapy Oncology Group head and neck trials. (2004) (2)
- Carcinomas of the oropharynx treated with hyperfractionated radiation therapy on Radiation Therapy Oncology Group Protocol 8313. (1994) (2)
- Chapter 26 – NITROSOUREAS IN THE TREATMENT OF MULTIPLE MYELOMA (1981) (2)
- Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804. (1982) (2)
- Methodology and research by the Radiation Therapy Oncology Group (RTOG). (2000) (2)
- Chlorozotocin: phase II evaluation in patients with myeloma. (1984) (2)
- STRATEGIES IN ADVANCED HEAD AND NECK CANCER — CURRENT STATUS AND FUTURE DIRECTIONS (1999) (1)
- MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study. (1981) (1)
- Evaluation of bleomycin, adriamycin, and vinblastine in combination therapy for advanced testicular tumors. (1976) (1)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. (2001) (1)
- RTOG ALTERED FRACTIONATION TRIALS (1992) (1)
- Reply to Emotional Well‐Being Does Not Predict Survival in Head and Neck Cancer Patients (2008) (1)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Translational Research Program. (2001) (1)
- Study of methyl-CCNU(NSC-95441) in the treatment of lung cancer. (1973) (1)
- 115 Design and analyses of clinical trials (1996) (1)
- Second malignancies in patients successfully treated for Hodgkin's disease (1979) (1)
- Flowcytometric quantification of the proliferation-associated nuclear antigen P105 and DNA content predicts local-regional control in advanced head and neck cancers: Results of RTOG 91-08 (1993) (1)
- Statistical response to Dr. J. M. Brown, IJROBP 32:883-885; 1995. (1995) (1)
- Status of fast neutron radiotherapy for non-small cell lung cancer (1985) (1)
- Group organizational structure (2001) (1)
- Outcome comparisons of four radiation therapy oncology group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: Encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT) (2004) (1)
- Gastrointestinal cancer committee (2001) (1)
- Microvessel density (mvd)≥60 does not predict for outcome in advanced head and neck squamous cell carcinoma (HNSCC): results of a prospective study from the RTOG 90-03 trial (2001) (1)
- Surrogate endpoints for overall survival (OS) in head and neck squamous cell carcinoma (HNSCC): Evaluation using individual data of 23,737 patients (2007) (1)
- Severe neurotoxicity with methyl G: CALGB experience. (1982) (1)
- Proceedings of the 38th Annual ASTRO Meeting139 Androgen suppression plus radiation vs. radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial RTOG 85-31) (1996) (1)
- [Achondroplastic dwarfism]. (1976) (1)
- Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132. (2016) (1)
- The TAME Risk Classification System: Acute Toxicity Burden and IPD Analysis of RTOG 90–03 (2005) (1)
- 2161 The impact of radiation dose and fractionation on the risk factor of radiation pneumonitis on four radiation therapy oncology group (RTOG) lung cancer trials (1997) (1)
- Dosimetry review process for head and neck (H&N) cancer trials conducted by radiation therapy oncology group (RTOG) (1989) (0)
- Quality of life (QOL) variables influence local regional control in radiation therapy oncology group (RTOG) headsneck trials (9003 and 9111) (2004) (0)
- The Radiation Therapy Oncology Group: an update of clinical research activities. (1991) (0)
- The Radiation Therapy Oncology Group: an outline of clinical research activities. (1988) (0)
- Hyperfractionated or accelerated radiotherapy in head and neck cancer : a fractional benefit? Commentary : a meta-analysis. Commentary (2006) (0)
- 02A Log-rank statistic for testing interaction effect in a 2 × 2 factorial design and its use in sample size determination (1994) (0)
- Abstract B54: Coordinate RB/PTEN tumor suppressor loss: Drives aggressive invasive behavior and is strongly associated with the progression of ductal carcinoma to invasive breast cancer (2013) (0)
- % SE At risk % SE At risk % SE At risk % SE At risk (2002) (0)
- Abstract of ASTRO scientific paper to be presentedPhase I/II study, combination of radiotherapy and hyperthermia in patients with deep-seated malignant tumors: Report of a pilot study by the radiation therapy oncology group (1989) (0)
- RTOG clinical trials with etanidazole (1993) (0)
- Methyl GAG. I. Report of toxicity (1981) (0)
- Combined-Modal i ty Therapy for Esophageal Cancer : High-Dose Versus Standard-Dose Radiat ion Therapy (2002) (0)
- Gender as a Determinant of Palliative Radiotherapy: A Patterns-of-Care-Study Analysis (1994) (0)
- r etinoblastoma and Phosphate and t ensin Homolog t umor Suppressor s: i mpact on Ductal c arcinoma i n Situ Progression (2012) (0)
- Sample size and duration of follow-up for stratified clinical trials (1984) (0)
- The radiation therapy oncology group: An update of clinical research activities (1991) (0)
- Clinical experiences in multi-institutional trials-RTOG (1993) (0)
- Verification of prognastic factors in multicenter clinical trials (1984) (0)
- Comparison of intra-arterial cisplatin and radiation therapy (RT) to other radiation therapy oncology group (RTOG) regimens using standard or accelerated RT with or without concurrent chemotherapy in patients with stage IV-T4 head and neck cancer (2004) (0)
- Methotrexate vm 26 41 o demethyl 1 o 4 6 o 2 thenylidene beta d glucopyranosyl epi podophyllo toxin procarbazine and dexamethasone in the treatment of refractory lymphoma (1981) (0)
- alkylating-agent therapy: a study of the CALGB Improved survival of increased-risk myeloma patients on combined triple- (2011) (0)
- Optimizing Sensory, Rheologic and Swallowing Parameters in the Development of Biophysically Designed Beverages for Swallowing Impaired Elders (2009) (0)
- The results of high energy fast neutron dose optimization studies in the head and neck, thorax, and pelvis (1986) (0)
- Randomized combined modality trial in small cell carcinoma of the lung. [Complications of chemotherapy and radiotherapy] (1980) (0)
- Fast neutron therapy for malignant astrocytomas. A review. (1986) (0)
- Radiation therapy oncology: In regard to Fu et al., IJROBP 2000;48:7-16 [6] (multiple letters) (2002) (0)
- Nonparametric survival regression trees and application to three radiation therapy oncology group (RTOG) malignant glioma trials (1992) (0)
- The TAME adverse event summary and risk classification system: Analysis of the RTOG H&N Database (2005) (0)
- light chains: CALGB experience Response to therapy in IgG myeloma patients excreting lambda or kappa (2011) (0)
- P124 Subjective pathology tumor grading: Impact on design and analysis of radiation therapy oncology group (RTOG) prostate trial 8531 (1997) (0)
- Biostatistical analysis of results from clinical trials in radiation oncology (1987) (0)
- Balanced approach in clinical trial management (CTM) between modern technologies and practical realities (1998) (0)
- Chapter 16 – CCNU IN COMBINATION CHEMOTHERAPY FOR SMALL-CELL LUNG CANCER (1981) (0)
- A multivariate modelling system to predict initial complete response of superficial malignant tumors to combined hyperthermia and radiation therapy: An analysis of the RTOG hyperthermia registry (78-06) (1984) (0)
- Randomized study to evaluate efficacy of levamisole in patients with unresectable non-oat cell carcinoma of the lung treated with radiation therapy (1984) (0)
- Abstracts of ASTRO scientific papers to be presentedLong term results of treatment of cervix cancer in the USA in 1973, 1978, and 1983 (1993) (0)
- Statistical power for a long term survival trial for an elderly population (1998) (0)
- Preliminary results of combined radiation and chemotherapy in the treatment of small cell carcinoma of the lung (a randomized study of cancer and leukemia group b) (1981) (0)
- Are cancer researchers speaking the same language? (1990) (0)
- Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long term results of a clinical cooperative group protocol, Trog 89-02 (1998) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas F. Pajak?
Thomas F. Pajak is affiliated with the following schools:
